None listed
Conditions
Brief summary
This trial is designed to show that routine hilar lymphadenectomy compared to no routine lymphadenectomy improves the rate of disease recurrence within 2 years after surgery in patients undergoing resection of CRC liver metastases
Interventions
Group A: Resection of colorectal liver metastases without routine hilar lymphadenectomy. However, patients with macroscopically enlarged lymph nodes undergo lymphadenectomy in accordance with current guidelines at the Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus Dresden. These patients will be analyzed in the intention-to-treat population. Group B: Routine hilar lymphadenectomy First, exploration of the abdomen and intraoperative ultrasound are performed to assess the extent of intrahepatic and potential extrahepatic disease and to confirm resectability. Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases. Following cholecystectomy in a fundus-first fashion, hilar lymphadenectomy is carried out including defined groups of lymph nodes (nomenclature of the lymph nodes according to the Japanese classification of gastric cancer). The groups of lymph nodes at the following sites will be resected : Common hepatic artery, Coeliac trunk, duodenal ligament, hepatic artery, Hepatoduodenal ligament, portal vein/bile duct. The duration of each procedure is approximately 200 minutes
Sponsors
Study design
Eligibility
Inclusion criteria
Patients scheduled for resection of colorectal cancer liver metastases. Patients undergoing simultanous resection of the primary tumor together with liver metastases may also be enrolled in the trial Patients scheduled for curative (R0) resection No evidence of extrahepatic disease No history of previous hilar lymphadenectomy Age equal or greater than 18 years Written Informed consent
Exclusion criteria
Expected lack of compliance Impaired mental state or language problems History of another primary cancer, except: Curatively treated in situ cervical cancer or curatively resected non-melanoma skin cancer Other primary solid tumour curatively treated with no known active disease present and no treatment administered for up to 5 years prior to randomisation